Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations
Language English Country Netherlands Media print-electronic
Document type Journal Article
PubMed
22676847
DOI
10.1016/j.jns.2012.05.036
PII: S0022-510X(12)00264-X
Knihovny.cz E-resources
- MeSH
- Adult MeSH
- Glatiramer Acetate MeSH
- Immunosuppressive Agents pharmacology therapeutic use MeSH
- Interferon-beta pharmacology therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Peptides pharmacology therapeutic use MeSH
- T-Lymphocytes, Regulatory immunology MeSH
- Multiple Sclerosis, Relapsing-Remitting drug therapy immunology MeSH
- T-Lymphocytes drug effects immunology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Glatiramer Acetate MeSH
- Immunosuppressive Agents MeSH
- Interferon-beta MeSH
- Peptides MeSH
INTRODUCTION: Multiple sclerosis (MS) is a chronic disease characterized by demyelination and chronic inflammation of the central nervous system (CNS). Many of the immune cells including T and B cells seem to be involved in disease pathogenesis by inducing or controlling the immune responses in the nervous system of MS patients. The objective of this study was to evaluate the differences in subpopulations of T cells between MS patients and healthy controls and the effects of interferon beta (INF-beta) and glatiramer acetate (GA) treatment on T cell subpopulations. MATERIAL AND METHODS: We have investigated the frequency of subpopulations of T cells using flow cytometry in 84 relapsing-remitting MS patients; forty-five patients started treatment with INF-beta and eighteen patients with GA, twenty-one patients were not treated. We collected blood samples at the beginning and after 6 and 12 months. RESULTS: We observed a significant decrease in CD4(+)CD25(+) Treg cells (p=0.03) and a significant increase in T helper cells (p=0.002) and central memory T cells (p=0.03) in MS patients compared to healthy controls. After INF-beta therapy, we demonstrated a significant increase in naive T cells (p=0.008), a decline in central memory T cells (p=0.01). After GA therapy, we observed a significant increase in naive T cells (p=0.04), a decrease in central memory T cells (p=0.03) and an increase in T-suppressor cells (p=0.008). CONCLUSION: In conclusion, we demonstrated the imbalance of T-cell subpopulations in MS patients and the potential benefit of DMD (disease modifying drugs) treatment on its restoration.
References provided by Crossref.org